These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

194 related items for PubMed ID: 9316655

  • 1. Evaluation of PSA, free PSA, PSMA, and total and bone alkaline phosphatase levels compared to bone scans in the management of patients with metastatic prostate cancer.
    Murphy GP, Troychak MJ, Cobb OE, Bowes VA, Kenny RJ, Barren RJ, Kenny GM, Ragde H, Holmes EH, Wolfert RL.
    Prostate; 1997 Oct 01; 33(2):141-6. PubMed ID: 9316655
    [Abstract] [Full Text] [Related]

  • 2. Comparison of serum prostate specific membrane antigen, prostate specific antigen, and free prostate specific antigen levels in radical prostatectomy patients.
    Douglas TH, Morgan TO, McLeod DG, Moul JW, Murphy GP, Barren R, Sesterhenn IA, Mostofi FK.
    Cancer; 1997 Jul 01; 80(1):107-14. PubMed ID: 9210715
    [Abstract] [Full Text] [Related]

  • 3. Evaluation and comparison of two new prostate carcinoma markers. Free-prostate specific antigen and prostate specific membrane antigen.
    Murphy GP, Barren RJ, Erickson SJ, Bowes VA, Wolfert RL, Bartsch G, Klocker H, Pointner J, Reissigl A, McLeod DG, Douglas T, Morgan T, Kenny GM, Ragde H, Boynton AL, Holmes EH.
    Cancer; 1996 Aug 15; 78(4):809-18. PubMed ID: 8756376
    [Abstract] [Full Text] [Related]

  • 4. Serum bone alkaline phosphatase levels enhance the clinical utility of prostate specific antigen in the staging of newly diagnosed prostate cancer patients.
    Lorente JA, Valenzuela H, Morote J, Gelabert A.
    Eur J Nucl Med; 1999 Jun 15; 26(6):625-32. PubMed ID: 10369948
    [Abstract] [Full Text] [Related]

  • 5. Prostate carcinoma staging. Clinical utility of bone alkaline phosphatase in addition to prostate specific antigen.
    Morote J, Lorente JA, Encabo G.
    Cancer; 1996 Dec 01; 78(11):2374-8. PubMed ID: 8941009
    [Abstract] [Full Text] [Related]

  • 6. Comparison of phosphatase isoenzymes PAP and PSA with bone scan in patients with prostate carcinoma.
    Amico S, Liehn JC, Desoize B, Larbre H, Deltour G, Valeyre J.
    Clin Nucl Med; 1991 Sep 01; 16(9):643-8. PubMed ID: 1718651
    [Abstract] [Full Text] [Related]

  • 7. Predicting radionuclide bone scan findings in patients with newly diagnosed, untreated prostate cancer: prostate specific antigen is superior to all other clinical parameters.
    Chybowski FM, Keller JJ, Bergstralh EJ, Oesterling JE.
    J Urol; 1991 Feb 01; 145(2):313-8. PubMed ID: 1703240
    [Abstract] [Full Text] [Related]

  • 8. Routine bone scans in patients with prostate cancer related to serum prostate-specific antigen and alkaline phosphatase.
    Wymenga LF, Boomsma JH, Groenier K, Piers DA, Mensink HJ.
    BJU Int; 2001 Aug 01; 88(3):226-30. PubMed ID: 11488734
    [Abstract] [Full Text] [Related]

  • 9. Bone alkaline phosphatase and prostate-specific antigen in the monitoring of prostate cancer.
    Cooper EH, Whelan P, Purves D.
    Prostate; 1994 Nov 01; 25(5):236-42. PubMed ID: 7526352
    [Abstract] [Full Text] [Related]

  • 10. Response in bone turnover markers during therapy predicts overall survival in patients with metastatic prostate cancer: analysis of three clinical trials.
    Som A, Tu SM, Liu J, Wang X, Qiao W, Logothetis C, Corn PG.
    Br J Cancer; 2012 Oct 23; 107(9):1547-53. PubMed ID: 23033003
    [Abstract] [Full Text] [Related]

  • 11. [Relationship of serum prostate-specific antigen and alkaline phosphatase levels with bone metastases in patients with prostate cancer].
    Wang ZL, Wang XF.
    Zhonghua Nan Ke Xue; 2005 Nov 23; 11(11):825-7. PubMed ID: 16333960
    [Abstract] [Full Text] [Related]

  • 12. More advantages in detecting bone and soft tissue metastases from prostate cancer using 18F-PSMA PET/CT.
    Pianou NK, Stavrou PZ, Vlontzou E, Rondogianni P, Exarhos DN, Datseris IE.
    Hell J Nucl Med; 2019 Nov 23; 22(1):6-9. PubMed ID: 30843003
    [Abstract] [Full Text] [Related]

  • 13. Clinical efficacy of bone alkaline phosphatase and prostate specific antigen in the diagnosis of bone metastasis in prostate cancer.
    Lorente JA, Morote J, Raventos C, Encabo G, Valenzuela H.
    J Urol; 1996 Apr 23; 155(4):1348-51. PubMed ID: 8632571
    [Abstract] [Full Text] [Related]

  • 14. Prediction of bone metastases by combination of tartrate-resistant acid phosphatase, alkaline phosphatase and prostate specific antigen in patients with prostate cancer.
    Ozu C, Nakashima J, Horiguchi Y, Oya M, Ohigashi T, Murai M.
    Int J Urol; 2008 May 23; 15(5):419-22. PubMed ID: 18452459
    [Abstract] [Full Text] [Related]

  • 15. Prostate-specific antigen as a unique routine test in monitoring therapy for inoperable prostate cancer: comparison with radionuclide bone scan and prostatic acid phosphatase.
    Barichello M, Gion M, Bonazza A, Delli Ponti US, Bolgan A, Contemori GP, Barioli P, Capitanio G, Pecori B, Omacini S.
    Eur Urol; 1995 May 23; 27(4):295-300. PubMed ID: 7544735
    [Abstract] [Full Text] [Related]

  • 16. Bone scintigraphy as a new imaging biomarker: the relationship between bone scan index and bone metabolic markers in prostate cancer patients with bone metastases.
    Wakabayashi H, Nakajima K, Mizokami A, Namiki M, Inaki A, Taki J, Kinuya S.
    Ann Nucl Med; 2013 Nov 23; 27(9):802-7. PubMed ID: 23828554
    [Abstract] [Full Text] [Related]

  • 17. Skeletal alkaline phosphatase in the metastatic workup of patients with prostate cancer.
    Wolff JM, Ittel T, Boeckmann W, Reinike T, Habib FK, Jakse G.
    Eur Urol; 1996 Nov 23; 30(3):302-6. PubMed ID: 8931961
    [Abstract] [Full Text] [Related]

  • 18. Aminoterminal propeptide of type I collagen and bone alkaline phosphatase in the study of bone metastases associated with prostatic carcinoma.
    Díaz-Martín MA, Traba ML, De La Piedra C, Guerrero R, Méndez-Dávila C, De La Peña EG.
    Scand J Clin Lab Invest; 1999 Apr 23; 59(2):125-32. PubMed ID: 10353326
    [Abstract] [Full Text] [Related]

  • 19. Evaluation of prostate cancer patients receiving multiple staging tests, including ProstaScint scintiscans.
    Murphy GP, Snow PB, Brandt J, Elgamal A, Brawer MK.
    Prostate; 2000 Feb 01; 42(2):145-9. PubMed ID: 10617872
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of repeated PSMA PET-directed radiotherapy for oligorecurrent prostate cancer after initial curative therapy.
    Henkenberens C, Oehus AK, Derlin T, Bengel F, Ross TL, Kuczyk MA, Janssen S, Christiansen H, von Klot CAJ.
    Strahlenther Onkol; 2020 Nov 01; 196(11):1006-1017. PubMed ID: 32399639
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.